# US 2006/0217421 A1 · Fortifier

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0217421 A1
- Document ID: US20060217421A1
- Status: Published application
- Kind: A1
- Application number: 10/556,016
- Filed: 2004-05-06
- Published: 2006-09-28
- Earliest claimed: 2003-05-09
- Inventors: Hajimu Kurumatani; Mitsutaka Tamura
- Web page: https://patentgrep.com/patent/US20060217421A1

## CPC

- A61K 47/22: Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A61K 31/343: condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
- A61K 31/401: Proline; Derivatives thereof, e.g. captopril
- A61K 31/403: condensed with carbocyclic rings, e.g. carbazole
- A61K 31/404: Indoles, e.g. pindolol
- A61K 31/4178: not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A61K 31/4184: condensed with carbocyclic rings, e.g. benzimidazoles
- A61K 31/5585: having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 9/12: Antihypertensives
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 13/12: of the kidneys
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 307/93: condensed with a ring other than six-membered
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

An agent for enhancing therapeutic or prophylactic effect of administering an inhibitor of renin-angiotensin system, such as candesartan cilexetil, on renal diseases is disclosed. The agent comprises a specific prostaglandin I derivative such as beraprost sodium as an effective ingredient.

## Claims

### Claim 1

An enhancing agent for enhancing therapeutic or prophylactic effect of administering (a) renin-angiotensin system inhibitor(s) on (a) renal disease(s), comprising as an effective ingredient a prostaglandin I derivative represented by the Formula (I):
[wherein R1 is
(A) COOR2, wherein R2 is
hydrogen or a pharmaceutically acceptable cation,
2) C1-C12 straight alkyl or C3-C14 branched alkyl,
Z-R3, wherein Z is covalent bond, or straight or branched alkylene represented by CtH2t wherein t is an integer of 1 to 6, R3 is C3-C12 cycloalkyl or C3-C12 cycloalkyl substituted with 1 to 3 R4(s) wherein R4 is hydrogen or C1-C5 alkyl,
—(CH2CH2O)nCH3, wherein n is an integer of 1 to 5,
-Z-Ar1, wherein Z represents the same meanings described above, Ar1 is phenyl, α-naphthyl, β-naphthyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, α-furyl, β-furyl, α-thienyl, β-thienyl or substituted phenyl (wherein the substituent(s) is(are) at least one of chlorine, bromine, fluorine, iodine, trifluoromethyl, C1-C4 alkyl, nitro, cyano, methoxy, phenyl, phenoxy, p-acetamidebenzamide, —CH═N—NH—C(═O)—NH2, —NH—C(═O)-Ph, —NH—C(═O)—CH3 and —NH—C(═O)—NH2),
CtH2tCOOR4, wherein CtH2t and R4 represent the same meanings as described above,
—CtH2tN(R4)2, wherein CtH2t and R4 represent the same meanings as described above,
—CH(R5)—C—(═O)—R6, wherein R5 is hydrogen or benzoyl, and R6 is phenyl, p-bromophenyl, p-chlorophenyl, p-biphenyl, p-nitrophenyl, p-benzamidephenyl or 2-naphthyl,
—CpH2p—W—R7, wherein W is —CH═CH—, —CH═CR7— or —C≡C—, wherein R7 is hydrogen, C1-C30 straight or branched alkyl or C1-C30 aralkyl, p is an integer of 1 to 5, or
10) —CH(CH2OR8)2, wherein R8 is C1-C30 alkyl or acyl,
(B) —CH2OH,
(C) —C(═O)N(R9)2, wherein R9 is hydrogen, C1-C12 straight alkyl, C3-C12 branched alkyl, C3-C12 cycloalkyl, C4-C13 cycloalkylalkylene, phenyl, substituted phenyl (wherein the definitions of the substituent(s) are the same as those described in (A) 5) mentioned above), C7-C12 aralkyl or —SO2R10 wherein R10 is C1-C10 alkyl, C3-C12 cycloalkyl, phenyl, substituted phenyl (wherein the definition(s) of the substituent(s) is(are) the same as those described in (A) 5) mentioned above), or C7-C12 aralkyl, wherein the two R9s may be the same or different, with the proviso that when one of them is —SO2R10, the other R9 is not —SO2R10, or
(D) —CH2OTHP (wherein THP is tetrahydropyranyl),
A is
—(CH2)m—
—CH═CH—CH2—,
—CH2—CH═CH—,
—CH2—O—CH2—,
—CH═CH—,
—O—CH2— or
7) —C≡C—, wherein m is an integer of 1 to 3,
Y is hydrogen, C1-C4 alkyl, chlorine, bromine, fluorine, formyl, methoxy or nitro,
B is —X—C(R11)(R12)OR13, wherein R11 is hydrogen or C3-C4 alkyl, R13 is hydrogen, C1-C14 acyl, C6-C15 aroyl, tetrahydropyranyl, tetrahydrofuranyl, 1-ethoxyethyl or t-butyl,
X is
—CH2—CH2—
—CH═CH— or
—C≡C—,
R12 is
C1-C12 straight alkyl, C3-C14 branched alkyl,
-Z-A2, wherein Z represents the same meanings as described above, Ar2 is phenyl, α-naphthyl, β-naphthyl, or phenyl substituted with at least one of chlorine, bromine, fluorine, iodine, trifluoromethyl, C1-C4 alkyl, nitro, cyano, methoxy, phenyl and phenoxy,
—CtH2tOR14, wherein CtH2t represents the same meanings as described above, R14 is C1-C6 straight alkyl, C3-C6 branched alkyl, phenyl, phenyl substituted with at least one of chlorine, bromine, fluorine, iodine, trifluoromethyl, C1-C4 alkyl, nitro, cyano, methoxy, phenyl or phenoxy-substituted phenyl, cyclopentyl, cyclohexyl, cyclopentyl substituted with 1 to 4 C1-C4 straight alkyl and cyclohexyl substituted with 1 to 4 C1-C4 straight alkyl,
-Z-R3, wherein Z and R3 represent the same meanings as mentioned above,
—CtH2t—CH═C(R15)R16, wherein CtH2t represents the same meanings as mentioned above, R15 and R16 represent hydrogen, methyl, ethyl, propyl or butyl, or
6) —CuH2u—C≡C—R17, wherein u is an integer of 1 to 7, CuH2u is straight or branched alkylene, and R17 is C1-C6 straight alkyl,
E is hydrogen or —OR18, wherein R18 is C1-C12 acyl, c7-C15 aroyl or R2 (wherein R2 represents the same meanings as described above),
said formula includes d-isomers, l-isomers and racemic compounds].

### Claim 2 (depends on 1)

The enhancing agent according to claim 1, wherein in said Formula (I),
R1 is COOR2,
wherein R2 is hydrogen or a pharmaceutically acceptable cation,
A is
1) —(CH2)m—
2) —CH2—CH═CH—
wherein m is an integer of 1 to 3,
Y is hydrogen,
B is —X—C(R11)(R12)OR13,
wherein R11 and R13 is hydrogen, X is
1) —CH═CH—
2) —C≡C—,
R12 is
1) -Z-Ar2
wherein Z is covalent bond, or straight or branched alkylene represented by CtH2t wherein t is an integer of 1 to 6, Ar2 is phenyl, α-naphthyl, β-naphthyl, or phenyl substituted with at least one of chlorine, bromine, fluorine, iodine, trifluoromethyl, C1-C4 alkyl, nitro, cyano, methoxy, phenyl and phenoxy, or
2) -Z-R3
wherein Z represents the same meanings as described above, R3 is C3-C12 cycloalkyl, or
3) —CuH2u—C≡C—R17
wherein u is an integer of 1 to 7, CuH2u is straight or branched alkylene, and R17 is C1-C6 straight alkyl,
said formula includes d-isomers, 1-isomers and racemic compounds.

### Claim 3 (depends on 1)

The enhancing agent according to claim 1, wherein in said Formula (I),
R1 is COOR2, wherein R2 is hydrogen or a pharmaceutically acceptable cation,
A is —(CH2)m—, wherein m is an integer of 1 to 3,
Y is hydrogen,
B is —X—C(R11)(R12)OR13, wherein R11 and R13 is hydrogen,
X is —CH═CH—,
R12 is —CuH2u—C≡C—R17, wherein u is an integer of 1 to 7, CuH2u is straight or branched alkylene, and R17 is C1-C6 straight alkyl,
E is hydrogen or —OR18, wherein R18 is R2 (wherein R2 represents the same meanings as described above),
said formula includes d-isomers, l-isomers and racemic compounds.

### Claim 4 (depends on 1)

The enhancing agent according to claim 1, wherein said prostaglandin I derivative is beraprost or pharmaceutically acceptable salt or ester thereof.

### Claim 5 (depends on 1, 2, 3, 4)

The enhancing agent according to any one of claims 1 to 4, wherein said renin-angiotensin system inhibitor is an ACE inhibitor.

### Claim 6 (depends on 5)

The enhancing agent according to claim 5, wherein said ACE inhibitor is selected from the group consisting of enalapril maleate, alacepril, delapril, ramipril, captopril, lisinopril, benazepril hydrochloride, libenzapril, quinaprilat, imidapril hydrochloride, zofenopril calcium, fosinopril sodium, cilazapril, temocapril hydrochloride, spirapril hydrochloride, perindopril erbumine, moexipril hydrochloride, trandolapril, ceronapril hydrate, utibapril, omapatrilat, Sampatrilat, and their pharmaceutically acceptable salts.

### Claim 7 (depends on 1, 2, 3, 4)

The enhancing agent according to any one of claims 1 to 4, wherein said renin-angiotensin system inhibitory substance is a compound having antagonistic action against angiotensin II receptor.

### Claim 8 (depends on 7)

The enhancing agent according to claim 7, wherein said compound having antagonistic action against angiotensin II receptor is selected from the group consisting of losartan, eprosartan, candesartan cilexetil, valsartan, telmisartan, irbesartan, tasosartan, olmesartan medoxomil, EXP-3174, zolasartan, saprisartan, elisartan potassium, ripisartan, milfasartan, forasartan, embusartan, fonsartan, E4177, YM358, ICI-D8731, TAK-536, CL-329167, pomisartan, candesartan, and their pharmaceutically acceptable salts.

### Claim 9 (depends on 8)

The enhancing agent according to claim 8, wherein said compound having antagonistic action against angiotensin II receptor is selected from the group consisting of losartan, eprosartan, candesartan cilexetil, valsartan, telmisartan, irbesartan, tasosartan, olmesartan medoxomil, EXP-3174, zolasartan, saprisartan, embusartan, candesartan, and their pharmaceutically acceptable salts.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The enhancing agent according to any one of claims 1 to 9, wherein said renal disease is diabetic nephropathy, glomerulonephritis, interstitial nephritis, acute renal failure, or chronic renal failure.

### Claim 11 (depends on 9)

The enhancing agent according to claim 9, wherein said renal disease is chronic renal failure.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The enhancing agent according to any one of claims 1 to 11, wherein said effect of administering renin-angiotensin system inhibitor is the effect to suppress elevation of serum creatinine with time during said renal disease(s).

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The enhancing agent according to any one of claims 1 to 11, wherein said effect of administering renin-angiotensin system inhibitory substance is the effect to suppress sequential decrease in the reciprocal of serum creatinine with time.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The enhancing agent according to any one of claims 1 to 11, wherein said effect of administering renin-angiotensin system inhibitor is the effect to suppress decrease in the glomerular filtration rate with time during said renal disease(s).

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

A therapeutic or prophylactic agent for renal disease, comprising as effective ingredients the enhancing agent according to any one of claims 1 to 14 and a renin-angiotensin system inhibitor.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

A kit for therapy or prophylaxis for renal diseases, comprising separately the enhancing agent according to any one of claims 1 to 14, and a drug containing as an effective ingredient a renin-angiotensin system inhibitor, wherein said kit is for administering the enhancing agent and the renin-angiotensin system inhibitor at the same time or at different times.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

A method for enhancing therapeutic or prophylactic effect of renin-angiotensin system inhibitor on renal disease, comprising administering the enhancing agent according to any one of claims 1 to 14 to a patient to whom (a) rennin-angiotensin system inhibitor(s) is(are) administered.

### Claim 18 (depends on 15, 16)

A method for treating or preventing a renal disease, comprising administering said therapeutic or prophylactic agent for renal diseases according to claim 15, or the drugs contained in the kit of therapeutic or prophylactic agents for renal diseases according to claim 16.

### Claim 19 (depends on 1, 2, 3, 4)

Use of said prostaglandin I derivative recited in any one of claims 1 to 4, for the production of an agent for enhancing the therapeutic or prophylactic effect of administering the renin-angiotensin system inhibitor on renal diseases.

### Claim 20 (depends on 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 19)

The use according to claim 19, wherein said enhancing agent is the enhancing agent according to any one of claims 5 to 14.
